UNKNOWN · LOW discovery confidence
Autologous total tumor mRNA loaded DOTAP liposome vaccine
Reported program or trial event; neither availability nor investment recommendation
Why this survived
Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.
MODEL INFERENCE · Source 1UNKNOWN
Next Best Diligence Question
What primary evidence resolves human efficacy for Autologous total tumor mRNA loaded DOTAP liposome vaccine in this exact treatment and indication context?
Why it matters and what could change
Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.
Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.
Likely source: Official trial arm-level results, primary PubMed human studies and protocols
Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.
Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.
Evidence completeness — coverage, not confidence
Human Signal: 0 / 5 gate components adjudicated
Cheap Truth: 0 / 6 gate components adjudicated
Clean Rights: 0 / 6 gate components adjudicated
Market Pull: 0 / 5 gate components adjudicated